Congratulations to Invivyd for the FDA Emergency Use Authorization of their monoclonal antibody, Pemgarda (pemivibart), as a pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents with moderate-to-severe immune compromise. ? Pemivibart is a recombinant human monoclonal IgG1, half-life extended antibody. It is designed for broad activity and has demonstrated in vitro neutralizing activity against previously circulating SARS-CoV-2 variants. ? Read the press release here: https://lnkd.in/eXpRi6qp ? #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment #COVID19 #FDA #EUA #Monoclonal #Healthcare #PreP #AntibodyProduction
Biointron
1 年
